시장보고서
상품코드
1110447

바이오시밀러 시장(제품별 : 재조합 당화 단백질, 재조합 비당화 단백질, 재조합 펩티드) : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2022-2031년)

Biosimilars Market (Product: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 232 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 바이오시밀러(Biosimilars) 시장에 대해 분석했으며, 과거·현재 성장 동향과 시장 기회, 향후 시장 지표와 인사이트(2022-2031년), 시장 매출 동향(2017-2031년), 세계 시장의 CAGR 전망(2022-2031년) 등을 조사했습니다.

목차

제1장 서문

제2장 가정과 두문자어

제3장 조사 방법

제4장 주요 요약 : 세계의 바이오시밀러 시장

제5장 시장 개요

  • 정의
  • 시장 지표
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회

제6장 시장 전망

  • 세계의 바이오시밀러 시장 분석과 예측(2017-2031년)
  • 세계의 바이오시밀러 시장 전망
  • 바이오시밀러 시장에 대한 참여 장벽
  • 바이오시밀러 보급 촉진요인
  • 파이프라인 분석
  • 규제 시나리오 평가
  • 업계의 주요 동향

제7장 세계의 바이오시밀러 시장 : 제품별 분석과 예측

  • 서론
  • 바이오시밀러 시장 규모 예측 : 제품별(금액 기준, 2017-2031년)
    • 재조합 당화 단백질
    • 재조합 비당화 단백질
    • 재조합 펩티드
  • 시장 매력 분석 : 제품별

제8장 세계의 바이오시밀러 시장 : 적응증별 분석과 예측

  • 서론
  • 바이오시밀러 시장 규모 예측 : 적응증별(금액 기준, 2017-2031년)
    • 만성질환
    • 종양
    • 자가면역질환
    • 감염증
    • 혈액질환
    • 성장호르몬결핍증
    • 기타
  • 시장 매력 분석 : 재료별

제9장 세계의 바이오시밀러 시장 : 지역별 분석과 예측

  • 지역별 전망
  • 세계 시장의 시나리오
  • 서론
  • 바이오시밀러 시장 규모 예측 : 지역별(금액 기준)
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역별

제10장 북미의 바이오시밀러 시장 분석과 예측

  • 주요 조사 결과
  • 시장 규모 예측 : 제품별(금액 기준, 2017-2031년)
  • 시장 규모 예측 : 적응증별(금액 기준, 2017-2031년)
  • 시장 규모 예측 : 국가별(금액 기준, 2017-2031년)
    • 미국
    • 캐나다
  • 북미의 바이오시밀러 시장 매력 분석

제11장 유럽의 바이오시밀러 시장 분석과 예측

제12장 아시아태평양의 바이오시밀러 시장 분석과 예측

제13장 라틴아메리카의 바이오시밀러 시장 분석과 예측

제14장 중동 및 아프리카의 바이오시밀러 시장 분석과 예측

제15장 경쟁 상황

  • 경쟁 매트릭스
  • 시장 점유율 분석 : 기업별(2021년)
  • 기업 개요
    • Pfizer, Inc.
    • Intas Pharmaceuticals Ltd.
    • Biocon
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH(Novartis의 한 부문)
    • Celltrion, Inc.
    • Amgen, Inc.
    • STADA Arzneimittel AG
    • Apotex Inc.(Apobiologix)
KSM 22.08.16

The report provides revenue of the global biosimilars market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biosimilars market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the biosimilars market.

The report delves into the competitive landscape of the global biosimilars market. Key players operating in the global biosimilars market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global biosimilars market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Biosimilars Market

5. Market Overview

  • 5.1. Definition
  • 5.2. Market Indicators
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunities

6. Market Outlook

  • 6.1. Global Biosimilars Market Analysis and Forecast, 2017-2031
  • 6.2. Global Biosimilars Market Outlook
  • 6.3. Entry Barriers to Biosimilars Market
  • 6.4. Factors Driving the Adoption of Biosimilars
  • 6.5. Pipeline Analysis
  • 6.6. Regulatory Scenario Assessment
  • 6.7. Key Industry Developments

7. Global Biosimilars Market Analysis and Forecast, by Product

  • 7.1. Introduction
  • 7.2. Biosimilars Market Value Forecast, by Product, 2017-2031
    • 7.2.1. Recombinant Glycosylated Proteins
      • 7.2.1.1. Monoclonal Antibodies
      • 7.2.1.2. Erythropoietin
      • 7.2.1.3. Others
    • 7.2.2. Recombinant Non-glycosylated Proteins
      • 7.2.2.1. Insulin
      • 7.2.2.2. Granulocyte Colony Stimulating Factor
      • 7.2.2.3. Recombinant Human Growth Factor
      • 7.2.2.4. Interferons
    • 7.2.3. Recombinant Peptides
  • 7.3. Market Attractiveness Analysis, by Product

8. Global Biosimilars Market Analysis and Forecast, by Indication

  • 8.1. Introduction
  • 8.2. Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 8.2.1. Chronic Diseases
    • 8.2.2. Oncology
    • 8.2.3. Autoimmune Diseases
    • 8.2.4. Infectious Diseases
    • 8.2.5. Blood Disorders
    • 8.2.6. Growth Hormone Deficiency
    • 8.2.7. Others
  • 8.3. Market Attractiveness Analysis, by Material

9. Global Biosimilars Market Analysis and Forecast, by Region

  • 9.1. Regional Outlook
  • 9.2. Global Scenario
  • 9.3. Introduction
  • 9.4. Biosimilars Market Value Forecast, by Region
    • 9.4.1. North America
    • 9.4.2. Europe
    • 9.4.3. Asia Pacific
    • 9.4.4. Latin America
    • 9.4.5. Middle East & Africa
  • 9.5. Market Attractiveness Analysis, by Region

10. North America Biosimilars Market Analysis and Forecast

  • 10.1. Key Findings
  • 10.2. North America Biosimilars Market Value Forecast, by Product, 2017-2031
    • 10.2.1. Recombinant Glycosylated Proteins
      • 10.2.1.1. Monoclonal Antibodies
      • 10.2.1.2. Erythropoietin
      • 10.2.1.3. Others
    • 10.2.2. Recombinant Non-glycosylated Proteins
      • 10.2.2.1. Insulin
      • 10.2.2.2. Granulocyte Colony Stimulating Factor
      • 10.2.2.3. Recombinant Human Growth Factor
      • 10.2.2.4. Interferons
    • 10.2.3. Recombinant Peptides
  • 10.3. North America Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 10.3.1. Chronic Diseases
    • 10.3.2. Oncology
    • 10.3.3. Autoimmune Diseases
    • 10.3.4. Infectious Diseases
    • 10.3.5. Blood Disorders
    • 10.3.6. Growth Hormone Deficiency
    • 10.3.7. Others
  • 10.4. North America Biosimilars Market Value Forecast, by Country, 2017-2031
    • 10.4.1. U.S.
    • 10.4.2. Canada
  • 10.5. North America Biosimilars Market Attractiveness Analysis
    • 10.5.1. By Product
    • 10.5.2. By Indication
    • 10.5.3. By Country

11. Europe Biosimilars Market Analysis and Forecast

  • 11.1. Key Findings
  • 11.2. Europe Biosimilars Market Value Forecast, by Product, 2017-2031
    • 11.2.1. Recombinant Glycosylated Proteins
      • 11.2.1.1. Monoclonal Antibodies
      • 11.2.1.2. Erythropoietin
      • 11.2.1.3. Others
    • 11.2.2. Recombinant Non-glycosylated Proteins
      • 11.2.2.1. Insulin
      • 11.2.2.2. Granulocyte Colony Stimulating Factor
      • 11.2.2.3. Recombinant Human Growth Factor
      • 11.2.2.4. Interferons
    • 11.2.3. Recombinant Peptides
  • 11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 11.3.1. Chronic Diseases
    • 11.3.2. Oncology
    • 11.3.3. Autoimmune Diseases
    • 11.3.4. Infectious Diseases
    • 11.3.5. Blood Disorders
    • 11.3.6. Growth Hormone Deficiency
    • 11.3.7. Others
  • 11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. U.K.
    • 11.4.2. Germany
    • 11.4.3. France
    • 11.4.4. Italy
    • 11.4.5. Spain
    • 11.4.6. Rest of Europe
  • 11.5. Europe Biosimilars Market Attractiveness Analysis
    • 11.5.1. By Product
    • 11.5.2. By Indication
    • 11.5.3. By Country/Sub-region

12. Asia Pacific Biosimilars Market Analysis and Forecast

  • 12.1. Key Findings
  • 12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017-2031
    • 12.2.1. Recombinant Glycosylated Proteins
      • 12.2.1.1. Monoclonal Antibodies
      • 12.2.1.2. Erythropoietin
      • 12.2.1.3. Others
    • 12.2.2. Recombinant Non-glycosylated Proteins
      • 12.2.2.1. Insulin
      • 12.2.2.2. Granulocyte Colony Stimulating Factor
      • 12.2.2.3. Recombinant Human Growth Factor
      • 12.2.2.4. Interferons
    • 12.2.3. Recombinant Peptides
  • 12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 12.3.1. Chronic Diseases
    • 12.3.2. Oncology
    • 12.3.3. Autoimmune Diseases
    • 12.3.4. Infectious Diseases
    • 12.3.5. Blood Disorders
    • 12.3.6. Growth Hormone Deficiency
    • 12.3.7. Others
  • 12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. China
    • 12.4.2. India
    • 12.4.3. Japan
    • 12.4.4. Australia & New Zealand
    • 12.4.5. Rest of Asia Pacific
  • 12.5. Asia Pacific Biosimilars Market Attractiveness Analysis
    • 12.5.1. By Product
    • 12.5.2. By Indication
    • 12.5.3. By Country/Sub-region

13. Latin America Biosimilars Market Analysis and Forecast

  • 13.1. Key Findings
  • 13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017-2031
    • 13.2.1. Recombinant Glycosylated Proteins
      • 13.2.1.1. Monoclonal Antibodies
      • 13.2.1.2. Erythropoietin
      • 13.2.1.3. Others
    • 13.2.2. Recombinant Non-glycosylated Proteins
      • 13.2.2.1. Insulin
      • 13.2.2.2. Granulocyte Colony Stimulating Factor
      • 13.2.2.3. Recombinant Human Growth Factor
      • 13.2.2.4. Interferons
    • 13.2.3. Recombinant Peptides
  • 13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. Chronic Diseases
    • 13.3.2. Oncology
    • 13.3.3. Autoimmune Diseases
    • 13.3.4. Infectious Diseases
    • 13.3.5. Blood Disorders
    • 13.3.6. Growth Hormone Deficiency
    • 13.3.7. Others
  • 13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. Brazil
    • 13.4.2. Mexico
    • 13.4.3. Rest of Latin America
  • 13.5. Latin America Biosimilars Market Attractiveness Analysis
    • 13.5.1. By Product
    • 13.5.2. By Indication
    • 13.5.3. By Country/Sub-region

14. Middle East & Africa Biosimilars Market Analysis and Forecast

  • 14.1. Key Findings
  • 14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017-2031
    • 14.2.1. Recombinant Glycosylated Proteins
      • 14.2.1.1. Monoclonal Antibodies
      • 14.2.1.2. Erythropoietin
      • 14.2.1.3. Others
    • 14.2.2. Recombinant Non-glycosylated Proteins
      • 14.2.2.1. Insulin
      • 14.2.2.2. Granulocyte Colony Stimulating Factor
      • 14.2.2.3. Recombinant Human Growth Factor
      • 14.2.2.4. Interferons
    • 14.2.3. Recombinant Peptides
  • 14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. Chronic Diseases
    • 14.3.2. Oncology
    • 14.3.3. Autoimmune Diseases
    • 14.3.4. Infectious Diseases
    • 14.3.5. Blood Disorders
    • 14.3.6. Growth Hormone Deficiency
    • 14.3.7. Others
  • 14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.4.1. GCC Countries
    • 14.4.2. South Africa
    • 14.4.3. Rest of Middle East & Africa
  • 14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis
    • 14.5.1. By Product
    • 14.5.2. By Indication
    • 14.5.3. By Country/Sub-region

15. Competition Landscape

  • 15.1. Competition Matrix
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Strategic Overview
      • 15.3.1.5. SWOT Analysis
    • 15.3.2. Intas Pharmaceuticals Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Strategic Overview
      • 15.3.2.5. SWOT Analysis
    • 15.3.3. Biocon
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Strategic Overview
      • 15.3.3.5. SWOT Analysis
    • 15.3.4. Dr. Reddy's Laboratories Ltd.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Strategic Overview
      • 15.3.4.5. SWOT Analysis
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Strategic Overview
      • 15.3.5.5. SWOT Analysis
    • 15.3.6. Sandoz International GmbH (A Novartis Division)
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Strategic Overview
      • 15.3.6.5. SWOT Analysis
    • 15.3.7. Celltrion, Inc.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Strategic Overview
      • 15.3.7.5. SWOT Analysis
    • 15.3.8. Amgen, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Strategic Overview
      • 15.3.8.5. SWOT Analysis
    • 15.3.9. STADA Arzneimittel AG
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Strategic Overview
      • 15.3.9.5. SWOT Analysis
    • 15.3.10. Apotex Inc. (Apobiologix)
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Strategic Overview
      • 15.3.10.5. SWOT Analys
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제